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Individualised therapyAbstract Introduction: The use of chemotherapy in node-negative, (O)Estrogen Receptor
(ER)-positive breast cancer has changed signiﬁcantly since the introduction of Oncotype
DX to determine systemic recurrence risk based on tumour genomic signature.
Aims: This study aims to
1. Document longitudinal changes in chemotherapy use,
2. Assess the impact of new evidence on local protocol.
Methods: A cohort study was undertaken, including consecutive patients with early node-
negative, ER-positive breast cancer diagnosed between 2006 and May 2013, including a
period of prospective clinical trial (Trial Assigning Individualised Options for Treatment
(TAILORx)) recruitment. Data were collected regarding patient demographics, tumour clinic-
o-pathological features, Oncotype DX use and recurrence score and chemotherapy use. All
therapeutic decisions were made following multidisciplinary discussion, with adherence to
guidelines and consideration of trial protocol and Oncotype DX recurrence scores.
Results: 479 consecutive patients were included in the study, of whom 241 (50%) underwent
Oncotype DX testing, 97 as part of the TAILORx clinical trial. Oncotype DX testing began
on a trial basis in 2007 and until October 2011, only patients enrolled on TAILORx availed of
genomic proﬁling. From October 2011, Oncotype DX was used in all eligible patients as perIreland.
2764 T.P. McVeigh et al. / European Journal of Cancer 50 (2014) 2763–2770National Cancer Control Programme (NCCP) guidelines. A total of 216 (45%) patients
received chemotherapy. The use of chemotherapy changed in inverse proportion to the avail-
ability of the genomic assay. Of those patients in whom Oncotype DX was utilised, 138 (57%)
were spared chemotherapy.
Conclusion: This study validates the use of molecular testing in the rationalisation of systemic
therapy.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
1.1. Management of breast cancer
Disease free and overall survival rates from breast
cancer have increased steadily over the last several years
despite a trend towards less aggressive surgical tech-
niques [1]. Breast conserving surgery represents the gold
standard surgical approach to the breast, while the sur-
gical management of the axilla is trending increasingly
towards a more minimally invasive approach especially
in the case of limited nodal disease burden [2]. Enhanced
understanding of the molecular basis of breast cancer
has allowed targeting of hormonal therapy or immuno-
logic agents [3–5]. The use of systemic therapy in the
management of breast cancer has led to a dramatic
reduction in cancer-related mortality by virtue of eradi-
cation of micro-metastatic disease in the circulation [6].
The beneﬁt of adjuvant chemotherapy is most apparent
in those cases in which the cancer cannot be cured by
local treatment alone [7,8]. In those patients with
node-negative early-stage breast cancer, however, the
absolute beneﬁt of systemic treatment is modest [9],
but the associated potential adverse eﬀects are consider-
able. Therefore, in line with other breast cancer treat-
ment modalities, the application of chemotherapy is
becoming increasingly individualised, and over-treat-
ment avoided wherever possible. To this end, interna-
tional guidelines recommend inclusion of gene
expression analysis in risk stratiﬁcation and decision-
making in prescription of adjuvant systemic therapy
[10,11].
1.2. Breast cancer genomics
Our understanding of tumour behaviour may be
enhanced by gene expression analysis. The risk of dis-
tant spread or recurrence of a tumour may not simply
be a function of increasing size or temporal acquisition
of metastatic ability, but may exist as an inbuilt property
of the tumour from the very beginning of the neoplastic
process [8]. The use of chemotherapy is based tradition-
ally on factors providing prognostic information, but
the genomic proﬁle of a tumour may provide additional
information in predicting the recurrence risk of a
tumour, and the degree of beneﬁt associated with che-
motherapy [8,9].Oncotype DX (Genomic Health Inc., Redwood City,
CA) is a clinically validated twenty-one-gene genomic
assay that can quantify the risk of breast cancer recur-
rence [12–14]. The gene panel includes ﬁve reference
genes and sixteen cancer-related genes, including those
associated with cell proliferation, invasion and hormone
response. The test generates a recurrence score between
0 and 100 that correlates to the likelihood of disease
recurrence within 10 years of diagnosis. Prospective val-
idation of the assay was carried out using a cohort from
the National Surgical Adjuvant Breast and Bowel Pro-
ject (NSABP), trial B-14 and B-20 [13,14]. Patients in
these trials were divided into low-, intermediate- and
high-risk groups based on recurrence scores (<18, 18–
30 andP31, respectively). The additional chemotherapy
beneﬁt when added to hormonal therapy compared to
hormones alone was large in the high-risk group, and
minimal in the low-risk group. The beneﬁt in the inter-
mediate group was unclear [14]. The protocol of TAI-
LORx (Trial Assigning Individualised Options for
Treatment) has assigned diﬀerent deﬁnitions to risk cat-
egories, with ‘low risk’ deﬁned as scores less than 10,
high-risk greater than 26 and intermediate between 11
and 25, inclusive. This new ‘intermediate-risk’ group is
randomised to receive either hormonal therapy alone
or combination chemotherapy and hormonal therapy
[15,16]. This trial will hopefully increase our understand-
ing of the utility of adjuvant systemic therapy in this
group. TAILORx recruitment in Ireland was run
through the All Ireland Cooperative Research Oncology
Group (ICORG), and interested and participating
oncologists were provided with information and educa-
tional materials at ICORGmeetings, by post and online.
The Health Service Executive (HSE) provides health
and personal social services for every Irish resident,
using taxation accrued public funds. A substantial pro-
portion of the Irish population also avails of private
health insurance from a variety of insurance brokers.
Ireland was among the ﬁrst European countries to pub-
licly reimburse the Oncotype DX test from October
2011. Prior to this date, Oncotype DX had been avail-
able for use in this patient cohort in Ireland on trial
basis only, as part of the TAILORx trial [16]. From
October 2011, Oncotype DX was used in all eligible
patients as per national Irish Society of Medical Oncol-
ogy and National Cancer Control Program guidelines
[17]. Recruitment for this trial began in our institution
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Between May 2010 and October 2011, Oncotype DX
was included in only a small proportion (20%) of private
health insurance policies, and was not publicly available.
The test was therefore not routinely used in clinical
practice.2. Aims
This study aims to document longitudinal changes in
the uptake of genomic proﬁling technologies and sys-
temic chemotherapy, and to assess the impact of new
evidence on local protocol.Table 1
Patient and tumour characteristics.
Age at diagnosis (years) Median (range) 58 (30–89)
Age groups (n (%)) <40 18 (4)
40–49 78 (16)
50–64 250 (53)
>65 125 (27)
Size (mm) Median (range) 20 (10–50)
T-stage n (%)
T1 240 (51)
T2 233 (49)
Histological subtype n (%)
Ductal 364 (77)
Lobular 56 (12)
Colloid 23 (5)
Tubular 12 (3)
Mixed 5 (1)
Other 13 (3)
Grade n (%)
1 66 (14)
2 317 (67)
3 90 (19)3. Methods
A retrospective cohort study was undertaken.
Patients were included if their disease fulﬁlled the fol-
lowing criteria: unilateral, stage T1 or T2, between 10
and 50 mm in size, node-negative, (O)Estrogen Receptor
(ER)-positive and Her2/neu negative. The study group
comprised 471 consecutive female patients diagnosed
between January 2006 and May 2013. Patient demo-
graphic and tumour clinico-pathological data, Oncotype
DX recurrence scores and information regarding che-
motherapy treatment regimes, complications and
patient outcomes were obtained by chart review. Onco-
type DX testing was performed centrally at the Genomic
Health Laboratory, using paraﬃn-embedded tissue sam-
ples taken from the tumour. All tumour specimens were
analysed in-house in the department of pathology, and
interpretation validated by a dedicated breast patholo-
gist. All reports were discussed at a weekly monthly dis-
ciplinary meeting. Tumour grade was scored using
Elston–Ellis modiﬁcation of the Scarﬀ–Bloom–Richard-
son grading system (Nottingham grading system) [18],
based on assessment of tubule formation, nuclear pleo-
morphism and mitotic count. Tumours were staged as
per TNM staging system [19].
The use of chemotherapy in patients enrolled to the
TAILORx clinical trial was based on recurrence score
and randomisation as per protocol. The use of chemo-
therapy in patients managed outside this trial was
guided by recurrence score and decided based on a
case-by-case discussion at the multidisciplinary meeting,
and in full consultation with patients. All patients
received adjuvant hormonal therapy, and in the case
of breast conserving surgery, adjuvant radiotherapy.
The standard chemotherapy regime consisted of Doce-
taxel and Cyclophosphamide or Doxorubicin and
cyclophosphamide.
A comparative analysis was carried out across four
time intervals:
1. Period prior to availability of Oncotype DX in
Ireland (2006–September 2007).2. Period during TAILORx recruitment (September
2007–May 2010).
3. Period following TAILORx recruitment and prior
to public reimbursement (May 2010–October 2011).
4. Period in which Oncotype DX testing is part of
routine clinical practice (October 2011–May 2013).
All data were analysed using SPSS version 20.
4. Results
4.1. Patient demographics
Criteria for inclusion in this study included a diagno-
sis of unilateral, stage T1 or T2 tumours (650 mm in
maximum diameter), node-negative, ER-positive
HER2-negative breast cancer. Three patients had
tumours less than 1 cm and were excluded from analysis.
Five hundred consecutive female patients were diag-
nosed with tumours ﬁtting this molecular proﬁle over
the study period. Twenty-ﬁve of these patients were
excluded from analysis in the case of bilateral disease,
ipsilateral concomitant second tumour of diﬀerent mor-
phology or if the diagnosis pertained to a disease recur-
rence. Two patients had multifocal disease but overall
tumour burden measured <50 mm maximally. A total
of four hundred and seventy-three tumours in four-hun-
dred and seventy-one patients were then included in the
ﬁnal analysis. Patient and tumour clinico-pathological
data are outlined in Table 1. The majority of patients
were aged between 50 and 65 years (n = 250, 53%).
4.2. Time intervals
The use of Oncotype DX testing and adjuvant che-
motherapy across four intervals is outlined in Table 2.
Table 2
Treatment intervals, Oncotype DX and chemotherapy use.
Time period 2006–2007 2007–May 2010 June 2010–October 2011 October 2011–
May 2013
Total
Oncotype DX test availability Oncotype not
Available
Oncotype available on
trial only
Oncotype not publicly
reimbursed
Oncotype in
clinical use
Number of patients treated 54 (12) 198 (42) 73 (15) 147 (31) 471
Oncotype DX use (n (%)) 0 (0) 96 (48) 19 (26) 125 (85) 240
Chemotherapy use (n (%)) 34 (63) 100 (51) 33 (45) 47 (32) 216
Proportion of population with private
health insurance
49% 47% 48% 46%
Table 3
Recurrence risk groups and chemotherapy use.
Recurrence risk Oncotype score Trial Number of patients (n) Chemotherapy used (n (%))
Low 0–17 118 16 (14)
TAILORx 41 16 (39)
Oﬀ-trial 77 0 (0)
Intermediate 18–30 100 65 (65)
TAILORx 43 25 (58)
Oﬀ-trial 57 40 (70)
High P31 16 16 (100)
TAILORx 7 7 (100)
Oﬀ-trial 9 9 (100)
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increased exponentially since it has been available for
use in the public sector. Eighty-ﬁve percent of patients
(n = 125) managed in the most recent interval under-
went genomic proﬁling of their tumours as part of their
treatment. The use of chemotherapy has undergone a
stepwise reduction over the four intervals, having been
used in 63% of cases in the interval pre-Oncotype DX
availability, compared to 32% of cases in the interval
of routine Oncotype DX testing.
4.3. Chemotherapy drug costs
Chemotherapy drug-related costs reduced dramati-
cally in 2010 following the expiration of the patent on
Docetaxel. The cost in our institution of four cycles of
the TC (Docetaxel/Cyclophosphamide) fell from €5965
in 2006 to €483 in 2013.
4.4. Recurrence scores
A total of 240 (51%) Oncotype DX genomic tests
were performed over the study period. Of these, 96 were
performed as part of the TAILORx trial. Patients were
stratiﬁed into low-, moderate- and high-risk groups
based on recurrence scores, as per the deﬁnitions out-
lined by Paik et al. [14,20]. The majority of patients
(n = 118, 50%) had a low recurrence score. A minority
(n = 16, 7%) had a score in excess of 31 (high-risk).
The remaining patients (n = 100, 43%) were of interme-
diate risk. All patients with a high-risk score received
adjuvant chemotherapy (n = 16, 100%). Of patients witha low-risk score, 16 received chemotherapy (n = 16,
14%). All 16 patients were enrolled to the TAILORx
trial, and had a recurrence score in excess of 11, and
were randomised to chemotherapy as per protocol
[16]. Sixty-ﬁve (65%) of patients deemed to be of inter-
mediate recurrence risk were prescribed adjuvant che-
motherapy. Patients in this risk category were far
more likely to receive chemotherapy if they were not
being managed as part of the TAILORx trial (40
(70%)-versus-25 (58%)) (Table 3).
4.5. Chemotherapy use
Univariate analyses were performed to investigate
which factors inﬂuenced use of chemotherapy (Table 4).
Chemotherapy was more often prescribed in the case of
tumours of increasing grade (<0.001, X2), increasing size
(p = 0.012, Mann–Whitney) and increasing recurrence
score (p < 0.001, Mann–Whitney). The use of chemo-
therapy correlated inversely with age at diagnosis
(p < 0.001, Mann–Whitney). Chemotherapy use was
also signiﬁcantly inﬂuenced by the time period during
which patients were treated (p < 0.001, X2). Four
patients declined chemotherapy. Three of these patients
did not undergo genomic assessment, and the other
patient had an intermediate risk score and was not on
a clinical trial. One other patient withdrew from partic-
ipation in a clinical trial and did not have systemic che-
motherapy treatment.
These factors were then included in a multivariate
model (binary logistic regression, Table 5). Considering
traditional prognostic indicators such as grade and
Table 4
Univariate analysis: factors inﬂuencing prescribing of chemotherapy.
N Chemotherapy used p-Value
Interval Prior to Oncotype 54 34 (63) <0.001*
Trial period 198 100 (51)
Prior to reimbursement 73 33 (45)
Publicly reimbursed 147 47 (32)
Grade 1 66 12 (18) <0.001*
2 317 153 (48)
3 90 51 (57)
Age groups (years) 639 18 14 (78) <0.001*
40–49 78 52 (67)
50–64 250 119 (48)
65 125 29 (23)
Oncotype DX risk groups Low 118 16 (14) <0.001*
Intermediate 100 65 (65)
High 16 16 (100)
Chemotherapy prescribed No chemotherapy
Median age (range)/years 54 (31–77) 62 (30–89) <0.001
Median tumour size (range)/mm 22 (7–50) 19 (10–49) 0.012
Median Oncotype score (range) 24 (11–61) 14 (4–28) <0.001
* Chi-squared test.
 Independent Samples Mann–Whitney U test.
Table 5
Factors inﬂuencing chemotherapy prescribing overall.
Factor Signiﬁcance OR
Interval* <0.001
Oncotype available on trial only 0.049 0.49
Oncotype not publicly reimbursed 0.022 0.37
Oncotype routinely used <0.001 0.20
Grade <0.001
Grade 2 <0.001 5.37
Grade 3 <0.001 7.40
Size 0.029 1.03
Age <0.001 0.91
* Compared to interval prior to availability of Oncotype DX.
 Compared to grade I.
Table 6
Factors inﬂuencing chemotherapy prescribing following the introduc-
tion of Oncotype DX testing.
Factor Signiﬁcance OR
Interval 0.04
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ment, all factors retained signiﬁcance in inﬂuencing deci-
sion-making as regards prescription of chemotherapy.
However, when recurrence score was included in the
multivariate model (Table 6), the traditional prognostic
indicators (grade and tumour size) were not shown to be
independent factors in guiding chemotherapy use.
Patients were 1.32-times more likely to receive chemo-
therapy with each unit increase in recurrence score
(p < 0.001). The interval during which patients under-
went treatment remained a signiﬁcant predictive factor
(p = 0.04).
In those patients in whom Oncotype DX was not
used, traditional prognostic factors such as grade, size
and age were highly signiﬁcant in determining chemo-
therapy use (Table 8). In this cohort, time interval of
treatment was also found to impact on decision-making
(p = 0.045), with patients managed following the intro-
duction of Oncotype DX into clinical practice being
far less likely to receive chemotherapy than those
patients managed in the era pre-Oncotype DX availabil-
ity (OR 0.09, p = 0.008), despite a lack of formal tumour
genomic assessment.Oncotype not publicly reimbursed 0.15 0.32
Oncotype routinely used 0.017 0.41
Grade 0.24
Grade 2 0.15 2.17
Grade 3 0.78 1.22
Size 0.59 1.01
Age 0.04 0.96
Oncotype score <0.001 1.33
 Compared to period of trial recruitment.
 Compared to grade I.4.6. Follow up and disease recurrence
The median follow up in this series is 47 months (8–
97). Over the study period, 12 (2.5%) patients experi-
enced disease progression, relapse or a second cancer.
Two patients progressed to develop visceral metastases,
and one patient unfortunately succumbed to metastatic
disease of bone, brain and viscera. Five patients (1%)
developed metastases limited to bone. Three patients
Table 7
Factors inﬂuencing use of chemotherapy in intermediate-
risk patient.
Factor Signiﬁcance OR
TAILORx participation 0.13 0.47
Grade 0.016
Grade 2 0.004 13.84
Grade 3 0.018 12.09
Size 0.44 0.98
Age 0.05 0.94
Oncotype score 0.002 1.28
 Compared to grade I.
Table 8
Factors inﬂuencing chemotherapy use in patients in
whom Oncotype Dx was not used.
Factor Signiﬁcance OR
Interval* 0.045
Oncotype available on trial only 0.069 0.45
Oncotype not publicly
reimbursed
0.121 0.42
Oncotype routinely used 0.008 0.09
Grade 0.001
Grade 2 0.002 9.20
Grade 3 <0.0001 17.72
Size 0.03 1.06
Age <0.0001 0.84
* Compared to interval prior to availability of Oncotype
DX.
 Compared to grade I.
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dose chemotherapy. One patient had a recurrence score
of 36 and developed visceral metastases despite receiving
full dose chemotherapy. The ﬁve patients in whom bone
metastases were diagnosed had received hormonal
agents only. A further four patients developed contralat-
eral breast disease. One patient was diagnosed with a
contralateral breast cancer of diﬀerent morphology,
while three patients developed contralateral breast dis-
ease of similar morphology.
5. Discussion
It is well reported that variations in gene expression
patterns can inﬂuence breast cancer phenotype, and
clustering of gene expression patterns can be used to
these tumours into distinct molecular subgroups [3]. It
is recognised that each tumour has a unique gene expres-
sion proﬁle, and there may be diversity in tumour biol-
ogy and disease progression even between tumours of
the same molecular subtype [21]. These variations can
greatly inﬂuence intrinsic tumour behaviour, and, there-
fore, response to treatment and patient outcome.
Traditionally, the need for chemotherapy was
decided based on tumour clinico-pathological prognosticindicators, with factors such as age [22], tumour size,
nodal status, grade and receptor expression proﬁles
taken into consideration as predictors of recurrence risk
[23,24]. Generally, tumours <2 cm of grade 1 would not
be managed on endocrine therapy alone. Those patients
however, if recruited to TAILORx, underwent genomic
proﬁling and were randomised to treatment groups
according to protocol. Some traditional prognostic fac-
tors may reﬂect timing of cancer detection as opposed to
tumour biology [25], and may therefore miss some of the
patients that would accrue most survival beneﬁt from
systemic therapy, leading to potentially inappropriate
under-treatment [8]. Furthermore, these traditional
prognostic indicators lack speciﬁcity, resulting in over-
treatment of patients with potentially harmful adjuncts
of negligible beneﬁt beyond local curative resection,
radiation and systemic endocrine therapy [12].
The Oncotype DX 21-gene assay represents the ﬁrst
clinically validated multi-gene assay that can quantify
the likelihood of breast cancer recurrence [8]. The recur-
rence score generated in this test has been consistently
shown to directly impact decision-making in breast can-
cer management [25,26]. Treatment decisions among
medical oncologists for early breast cancer are variable
even with the use of gene assays [27,28]. A pooled anal-
ysis by Carlson and Roth [12] found the proportion of
patients with low-risk recurrence scores receiving che-
motherapy to range between 0 and 16% across fourteen
series (pooled mean 5.8%). In our series, 14% (n = 16) of
patients in this category received chemotherapy. It is
worth noting that all 16 of these patients were enrolled
in the TAILORx trial. These patients all had recurrence
scores greater than 11, necessitating their inclusion in
the trial arm. They were then randomised to receive che-
motherapy. Patients not enrolled to TAILORx were
spared chemotherapy in all cases of a low-risk recur-
rence score. All patients with a high-risk recurrence
score (n = 16, 100%) received chemotherapy whether
or not they were enrolled to a clinical trial. In other ser-
ies this proportion ranged between 72% and 100%
(pooled mean 83.4%) [12]. Patients found to have an
intermediate-risk recurrence score (18–30) received che-
motherapy in 65% cases. Patients were more likely to
receive chemotherapy if they were not enrolled to TAI-
LORx (n = 40 (70%)-versus-25 (58%)). This proportion
is higher than that reported in other series (range
23.9–65% [12]). When considering factors inﬂuencing
chemotherapy prescribing in this group alone (Table 7),
the absolute Oncotype score was signiﬁcant in inﬂuenc-
ing use of chemotherapy (OR 1.28 per unit increase).
TAILORx participation was not shown to be an inde-
pendent predictor of chemotherapy use when consider-
ing other factors such as Oncotype score, age at
diagnosis and tumour size and grade. Grade was found
to retain strong signiﬁcance in this group, with tumours
of grade 2 and grade 3 associated with a 13.8- and 12.1-
fold increased used of chemotherapy compared to
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considered (p = 0.016). This reﬂects a reversion back
to traditional prognostic indicators in the decision-mak-
ing process when faced with an indeterminate score.
The most striking ﬁnding of this series was the
observed stepwise reduction in chemotherapy use. Con-
sidering time intervals alone, this is unexpected, given
that the cost of systemic therapy has decreased drasti-
cally over the study period and yet is being utilised less
frequently. The application of Oncotype DX has previ-
ously been shown to inﬂuence decision-making in che-
motherapy-prescribing [29]. In this series, we have
shown the introduction of the 21-gene assay into the
clinical arena to have an inﬂuence on decision-making
among disciplinary teams independent of its direct use.
The concept that not all patients might beneﬁt from che-
motherapy by virtue of favourable tumour genomics has
translated into reduced application of systemic therapy
even in those patients in whom formal genomic apprai-
sal was not available. Traditional prognostic factors are
now only relied on in the case of an indeterminate result.
Validation of the Oncotype DX by level one evidence
[30] has led to a change in physician attitudes towards
risk stratiﬁcation and adjuvant chemotherapy use.6. Conclusion
The application of Oncotype DX has been success-
fully integrated into the treatment paradigm of patients
with early stage ER+, node-negative breast cancer in
our institution. Patients at lowest risk of disease recur-
rence on the basis of the test have been spared chemo-
therapy, while those found to be likely to receive most
survival beneﬁt from chemotherapy have all received
systemic treatment. Traditional prognostic factors
remain important in decision-making in patients of inde-
terminate scores. The introduction of Oncotype DX
testing into clinical practice in our institution has led
to reduction in the application of systemic therapy inde-
pendent of its actual use. Long-term data regarding
patient outcome are awaited but certainly short- and
medium-term results are favourable. This illustrates
the importance of continued adaptation of the clinical
team to new evidence in decision-making of breast can-
cer management.Conﬂict of interest statement
None declared.
References
[1] Heneghan HM, Prichard RS, Devaney A, et al. Evolution of
breast cancer management in Ireland: a decade of change. BMC
Surg 2009;9(1).
[2] Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs
no axillary dissection in women with invasive breast cancer andsentinel node metastasis: a randomized clinical trial. JAMA
2011;305(6):569–75.
[3] Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns
of breast carcinomas distinguish tumor subclasses with clinical
implications. Proc Natl Acad Sci USA 2001;98(19):10869–74.
[4] Perou CM, Sørile T, Eisen MB, et al. Molecular portraits of
human breast tumours. Nature 2000;406(6797):747–52.
[5] Lehmann BD, Bauer JA, Chen X, et al. Identiﬁcation of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest 2011;121(7):2750–67.
[6] Howe HL et al.. Women with multiple primary breast cancers
diagnosed within a ﬁve year period, 1994–1998. Breast Cancer
Res Treat 2005;90(3):223–32.
[7] Clarke M, Collins R, Davies C, et al. Polychemotherapy for early
breast cancer: an overview of the randomised trials. Lancet
1998;352(9132):930–42.
[8] Oakman C, Bessi S, Zafarana E, et al. Recent advances in
systemic therapy: new diagnostics and biological predictors
of outcome in early breast cancer. Breast Cancer Res 2009;
11(2):205.
[9] Paik S, Tang G, Shak S, et al. Gene expression and beneﬁt of
chemotherapy in women with node-negative, estrogen receptor-
positive breast cancer. J Clin Oncol 2006;24(23):3726–34.
[10] Harris L, Fritsche H, Mennel R, et al. American society of clinical
oncology 2007 update of recommendations for the use of tumor
markers in breast cancer. J Clin Oncol 2007;25(33):5287–312.
[11] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for
subtypes-dealing with the diversity of breast cancer: highlights of
the St Gallen international expert consensus on the primary
therapy of early breast cancer 2011. Ann Oncol
2011;22(8):1736–47.
[12] Carlson JJ, Roth JA. The impact of the Oncotype Dx breast
cancer assay in clinical practice: a systematic review and meta-
analysis. Breast Cancer Res Treat 2013;141(1):13–22.
[13] Cronin M, Pho M, Dutta D, et al. Measurement of gene
expression in archival paraﬃn-embedded tissues: development
and performance of a 92-gene reverse transcriptase-polymerase
chain reaction assay. Am J Pathol 2004;164(1):35–42.
[14] Paik S, Shak S, Tang G, et al. A multigene assay to predict
recurrence of tamoxifen-treated, node-negative breast cancer.
New Engl J Med 2004;351(27):2817–26.
[15] Sandberg MEC et al.. Estrogen receptor status in relation to risk
of contralateral breast cancer-a population-based cohort study.
PLoS ONE 2012;7(10).
[16] Sparano JA. TAILORx: Trial Assigning Individualized Options
for Treatment (Rx). Clin Breast Cancer 2006;7(4):347–50.
[17] Kelly CM. Oncotype-DX gene expression proﬁle and chemo-
therapy decision-making in patients with early stage breast
cancer. Irish Society of Medical Oncology guideline; 2011.
[18] Elston CW, Ellis IO. Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer:
experience from a large study with long-term follow-up. Histo-
pathology 1991;19(5):403–10.
[19] Edge SB, Compton CC. The American Joint Committee on
Cancer: the 7th edition of the AJCC cancer staging manual and
the future of TNM. Ann Surg Oncol 2010;17(6):1471–4.
[20] Tang G, Shak S, Paik S, et al. Comparison of the prognostic and
predictive utilities of the 21-gene recurrence score assay and
adjuvant! for women with node-negative, ER-positive breast
cancer: results from NSABP B-14 and NSABP B-20. Breast
Cancer Res Treat 2011;127(1):133–42.
[21] Sørlie T. Molecular portraits of breast cancer: tumour subtypes as
distinct disease entities. Eur J Cancer 2004;40(18):2667–75.
[22] Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-
negative, oestrogen-receptor-positive breast cancer: long-term
ﬁndings from National Surgical Adjuvant Breast and
Bowel Project randomised clinical trials. Lancet 2004;364(9437):
858–68.
2770 T.P. McVeigh et al. / European Journal of Cancer 50 (2014) 2763–2770[23] Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force
report: adjuvant therapy for breast cancer. JNCCN J Natl Comp
Cancer Netw 2006;4(suppl. 1):S-1–S-26.
[24] Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham
prognostic index in primary breast cancer. Breast Cancer Res
Treat 1992;22(3):207–19.
[25] Markopoulos C. Overview of the use of Oncotype DX((R)) as an
additional treatment decision tool in early breast cancer. Expert
Rev Anticancer Ther 2013;13(2):179–94.
[26] Hornberger J et al.. Clinical validity/utility, change in practice
patterns, and economic implications of risk stratiﬁers to predict
outcomes for early-stage breast cancer: a systematic review. J Natl
Cancer Inst 2012;104(14):1068–79.
[27] Drukker CA, Van Den Hout HC, Sonke GS, Brain E, et al. Risk
estimations and treatment decisions in early stage breast cancer:agreement among oncologists and the impact of the 70-gene
signature. Eur J Cancer 2014;50(6):1045–54.
[28] Zardavas D, Ades F, Spasojevic IB, Pugliano L, et al. Contro-
versial issues in early-stage breast cancer: a global collaborative
survey, supported by the European Society for Medical Oncology
(ESMO). Ann Oncol 2014;25(8):1558–62.
[29] Eiermann W, Rezai M, Ku¨mmel S, et al. The 21-gene recurrence
score assay impacts adjuvant therapy recommendations for er-
positive, node-negative and node-positive early breast cancer
resulting in a risk-adapted change in chemotherapy use. Ann
Oncol 2013;24(3):618–24.
[30] Harbeck N, Sotlar K, Wuerstlein R, Doisneau-Sixou S.
Molecular and protein markers for clinical decision making in
breast cancer: today and tomorrow. Cancer Treat Rev 2014;40(3):
434–44.
